tirzepatide sydney 𧬠New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve kidney function in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( Frontiers | Tirzepatide against obesity
Description
All randomly assigned participants were to undergo a planned 72-week treatment period that included a dose-escalation period of up to 20 weeks
Reduced risk of heart disease: Those who use Tirzepatide have less risk of heart disease and stroke
Tirzepatide has shown impressive success in clinical trials, with many patients experiencing significant reductions in body weight
Bolded values refer to statistically significant findings
A medically supervised Tirzepatide program focuses on creating sustainable weight management strategies while addressing each patients unique health concerns and lifestyle factors
